Table of contents
April 2005 Vol 4 No 4
In this issue
p263 | doi:10.1038/nrd1715
Editorial: Games without frontiers
p265 | doi:10.1038/nrd1707
News and Analysis
News
Long-term study proposed for COX2 inhibitors | PDF (235 KB)
p267 | doi:10.1038/nrd1712
News
Industry shrugs off NIH consulting ban | PDF (235 KB)
p268 | doi:10.1038/nrd1690
News
Cancer drugs could now discover X factor | PDF (235 KB)
p269 | doi:10.1038/nrd1713
News in Brief
MS treatment temporarily suspended | Novartis becomes biggest generic manufacturer | Treatments compete to lower cholesterol | PDF (235 KB)
p269 | doi:10.1038/nrd1714
Patent watch
Yale assigned Nobel Prize winner's patent | PDF (235 KB)
p270 | doi:10.1038/nrd1709
Patent watch
Hybrid too human to patent | PDF (235 KB)
p270 | doi:10.1038/nrd1710
Patent primer
Experimental use provision | PDF (235 KB)
p271 | doi:10.1038/nrd1699
An Audience With
John L. LaMattina | PDF (235 KB)
p272 | doi:10.1038/nrd1711
From the analyst's couch
BioPharma licensing and M&A trends | PDF (94 KB)
p273 | doi:10.1038/nrd1697
Fresh from the Pipeline
Azacitidine | PDF (111 KB)
p275 | doi:10.1038/nrd1698
Research Highlights
Antiviral drugs: Salubrious inhibition | PDF (88 KB)
p277 | doi:10.1038/nrd1703
Nuclear receptors: Choosing the right path | PDF (252 KB)
p278 | doi:10.1038/nrd1702
Screening: Hitting the hot spots | PDF (163 KB)
p278 | doi:10.1038/nrd1705
Kinase inhibitors: Surveying the kinome | PDF (146 KB)
p279 | doi:10.1038/nrd1704
G-Protein-coupled receptors: Setting traps for drug discovery | PDF (95 KB)
p280 | doi:10.1038/nrd1701
In brief
Virtual screening | Cardiovascular disease | Stroke | Kinases | PDF (95 KB)
p280 | doi:10.1038/nrd1706
Reviews
The evolving field of biodefence: therapeutic developments and diagnostics
James C. Burnett, Erik A. Henchal, Alan L. Schmaljohn & Sina Bavari
p281 | doi:10.1038/nrd1694
Protein drug stability: a formulation challenge
Sven Frokjaer & Daniel E. Otzen
p298 | doi:10.1038/nrd1695
Cellular processing of platinum anticancer drugs
Dong Wang & Stephen J. Lippard
p307 | doi:10.1038/nrd1691
Model organisms: Chemistry-to-gene screens in Caenorhabditis elegans
Andrew K. Jones, Steven D. Buckingham & David B. Sattelle
p321 | doi:10.1038/nrd1692
Osteoarthritis — an untreatable disease?
Heike A. Wieland, Martin Michaelis, Bernhard J. Kirschbaum & Karl A. Rudolphi
p331 | doi:10.1038/nrd1693
Perspectives
Innovation
How molecular profiling could revolutionize drug discovery
Roland B. Stoughton & Stephen H. Friend
p345 | doi:10.1038/nrd1696
